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Formulators face great challenges in adopting systematic approaches for designing self-nanoemulsifying 
formulations (SNEFs) for different drug categories. In this study, we aimed to build-up an advanced SNEF 
development framework for weakly basic lipophilic drugs, such as cinnarizine (CN). First, the influence 
of formulation acidification on CN solubility was investigated. Second, formulation self-emulsification 
in media with different pH was assessed. Experimentally designed phase diagrams were also utilized 
for advanced optimization of CN-SNEF. Finally, the optimized formulation was examined using cross 
polarizing light microscopy for the presence of liquid crystals. CN solubility was significantly enhanced 
upon external and internal acidification. Among the various fatty acids, oleic acid-based formulations 
showed superior self-emulsification in all the tested media. Surprisingly, formulation turbidity and droplet 
size significantly decreased upon equilibration with CN. The design was validated using oleic acid/
Imwitor308/Cremophor El (25/25/50), which showed excellent self-nanoemulsification, 43-nm droplet 
size (for CN-equilibrated formulations), and 88 mg/g CN solubility. In contrast to CN-free formulations, 
CN-loaded SNEF presented lamellar liquid crystals upon 50% aqueous dilution. These findings confirmed 
that CN-SNEF efficiency was greatly enhanced upon drug incorporation. The adopted strategy offers fast 
and accurate development of SNEFs and could be extrapolated for other weakly basic lipophilic drugs.
Uniterms: Self-nanoemulsifying formulations/solubility. Cinnarizine/lipophilic drugs. Acidification/
experimental design. Solubility enhancement.
INTRODUCTION
As a result of modern drug discovery practices, 
there has been a consistent rise in the number of newly 
discovered chemical entities that are considered poorly 
water-soluble drugs (PWSDs). Owing to their poor 
dissolution, these PWSDs often present low and erratic 
bioavailabilities. Pharmaceutical experts are therefore 
facing great challenges in formulating these entities 
into oral dosage forms with adequate bioavailability 
(Dahan, Hoffman, 2008). Among the various lipid-based 
formulations, self-nanoemulsifying formulations (SNEFs) 
represent one of the most promising candidates in terms of 
enhancing the in-vivo performance of orally administered 
PWSD (Bahloul et al., 2015). Compared with other drug 
delivery systems, SNEFs offer great advantages, including 
ease of manufacture and scaling-up, improved physical 
stability, and maximized drug entrapment capacity. Upon 
introduction to physiological media, no dissolution step 
would be required owing to the formation of a nano-
droplet size emulsion. This facilitates a higher rate and 
extent of absorption and therefore high and reproducible 
bioavailability values (Balakumar et al., 2013; Gupta, 
Kesarla, Omri, 2013). 
Current development approaches in the SNEF 
area are mostly empirical and consume large amounts 
of time and money (Dahan, Hoffman, 2008; Bahloul et 
al., 2015). SNEFs are commonly developed using the 
“trial and error approach” which involves changing one 
parameter at a time or the conventional “ternary phase 
diagrams” technique. These two methods require several 
experiments, hence resulting in high cost and long 
development periods (Bahloul, Lassoued, Sfar, 2014). In 
addition, some formulations might be mischaracterized 
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owing to inadequate testing conditions, as further 
mentioned in the “self-emulsification assessment section” 
of the current study. Many other limitations still restrict the 
potential usage of SNEFs, including the lack of predictive 
in-vitro tests, insufficient in-vivo drug precipitation 
studies, and lack of in vitro–in vivo correlations (IVIVC) 
(Bahloul et al., 2015). SNEF optimization for each drug 
is not an easy process. Only very specific excipient 
combinations will produce efficient self-nanoemulsifying 
systems. This could be confirmed by the vast amount of 
research performed in this area leading to only limited 
numbers of SNEF products in the pharmaceutical market 
(Gursoy, Benita, 2004; Elnaggar, El-Massik, Abdallah, 
2009; Bahloul et al., 2015).
Therefore, regarding in-vitro prospects, there is a 
need for an advanced approach to accelerate the design, 
characterization, and optimization of SNEFs and adopt a 
formulation design platform that suits similar drug models 
(Bahloul et al., 2015).
The aim of the current study is to build-up an 
advanced SNEF design framework for weakly basic 
lipophilic drugs. Cinnarizine (CN), a highly lipophilic 
compound (log P = 5.8) (Loftsson, Hreinsdóttir, Másson, 
2005), was selected as the model drug for the current 
study. CN is a weak base with Pka1 = 1.94 and Pka2 = 
7.47 (Tokumura et al., 1987). It shows a pH-dependent 
solubility that is 0.29 mg/mL at pH 2, 0.017 mg/mL 
at pH 5, and 0.002 mg/mL at pH 6.5 (Gu et al., 2005; 
Raghuvanshi, Pathak, 2014). Therefore, it is vital to 
consider the influence of formulation acidity and pH 
variation during the design of CN-SNEF (Shahba, 
Mohsin, Alanazi, 2012a). In the current study, we aim to 
bridge the gaps regarding critical characterization issues, 
explore the role of formulation acidification, and utilize 
the experimental design for a time-effective and accurate 
optimization of SNEFs for weakly basic lipophilic drugs.
MATERIAL AND METHODS
Material
Miglyol 810 (M810, medium chain triglycerides), 
Miglyol 812 (M812, medium chain triglycerides), Imwitor 
308 (I308, medium chain monoglycerides), and Imwitor 
988 (I988, medium chain mono/diglycerides) were kindly 
supplied by Sasol GmbH, Germany. Oleic acid (OL, long 
chain fatty acid C18) and Tween 80 (T80) were obtained 
from Avonchem, UK. Tween 85 (T85) was purchased 
from Merck-Schuchardt OHG, Germany. Tween 20 
(T20) was purchased from BDH, UK. Cremophor EL 
(Cr-El) and Cremophor RH40 (Cr-RH40) were supplied 
by BASF, Germany. CremerAc Capric acid (C10) 98/100 
and Cremer AC distilled coconut oil fatty acids (COFA) 
were kindly supplied by Cremer Oleo GmbH & Co. KG, 
Germany. Caprylic acid (C8) was purchased from Wuji 
Xinhui Chemical Co. Ltd, China. Sefsol 218 (S218), 
HCO-30, and HCO-60 were kindly provided by Nikko 
Chemicals, Japan. Lauroglycol 90 and Capmul PG-12 
were kindly supplied by Gattefosse, France and Abitec, 
USA, respectively. CN was supplied by FDC Limited, 
India.
Equilibrium solubility studies
The equi l ibr ium CN solubi l i ty  in  diverse 
formulations was determined according to previously 
reported studies (Baka, Comer, Takács-Novák, 2008) with 
some modifications. After at least a three-day equilibration 
period, samples were withdrawn, centrifuged, and assayed 
using ultra-performance liquid chromatography (UPLC) 
(Abdel-Hamid et al., 2012; Shahba, Mohsin, Alanazi, 
2012a). 
Self-emulsification assessment
A previously reported (Kommuru et al., 2001; 
Shahba, Mohsin, Alanazi, 2012b) visual test, used to assess 
self-emulsification efficiency, was modified and adopted 
for the current study. In accordance with routine practice, 
formulation dispersion in water was utilized as a fast and 
general tool to assess formulation self-emulsification 
efficiency. However, in the current study, it was proven 
that “formulation dispersion in water” was not sufficient 
alone because some formulations may show variable 
emulsification behaviors at different pH. 
To assess such formulations accurately, drug-
equilibrated formulations were dispersed under the 
following conditions:
Primarily, formulations were subjected to 1:400 
aqueous dilution in a 50.0 mL glass beaker, and the 
contents were gently mixed (~500 rpm) using a magnetic 
stirrer (Nekkanti et al., 2010; Shahba, Mohsin, Alanazi, 
2012b). Alternatively, formulations (20–30 mg) were 
diluted with 50.0 mL of 0.1 N HCl (pH 1.2) in order to 
mimic gastric pH. The contents were then gently mixed 
as previously described. Finally, 25.0 mL of ≈120 mM 
tribasic sodium phosphate solution was added to the latter 
media to reach a pH of 6.8, mimicking intestinal pH. The 
contents were again gently mixed as previously described. 
This step was very critical, particularly for weakly basic 
drugs whose behavior varies greatly depending on media 
pH.
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The formulations were evaluated on the basis of 
performance indicator tools, such as excipient miscibility, 
spontaneity, and homogeneity/dispersibility (Shahba, 
Mohsin, Alanazi, 2012b). 
Optical density
For further exploration of assessment results, the 
optical density (OD) of selected diluted formulations 
were examined at 600.0 nm using an UV-visible 
spectrophotometer (UVD-3200, Labomed Inc., USA) 
(Date, Nagarsenker, 2007; Thakkar et al., 2011). Prior 
to OD measurement, drug free and/or drug equilibrated 
formulations were subjected to 1:400 aqueous dilutions in 
a 50.0 mL glass beaker, and the contents were gently mixed 
using a magnetic stirrer (~500 rpm) (Nekkanti et al., 2010; 
Shahba, Mohsin, Alanazi, 2012b). Formulation clarity 
was categorized according to the following OD600 ranges: 
transparent: OD600 = 0.00-0.05, bluish: OD600 = 0.05-0.1, 
turbid: OD600 = 0.1-0.3, and milky: OD600 > 0.3 (Shahba, 
Mohsin, Alanazi, 2012b).
Droplet size analysis
The average droplet size of the diluted SNEF was 
examined using a Zetasizer Nano ZS (Malvern, UK). 
The formulations were diluted in distilled water at a ratio 
of 1:1000 v/v and mixed for 1 min prior to examination 
(Kommuru et al., 2001; Atef, Belmonte, 2008). 
Experimentally designed phase diagrams
Phase diagram studies often require large numbers 
of sample preparations, thereby requiring extensive time. 
In the current study, all phase diagrams were constructed 
using advanced experimental design in order to reduce 
the number of experiments, save time, and obtain a 
comprehensive analysis of the data. Design Expert® 
(version 9, Stat-Ease, Inc., USA) was used to construct 
the D-optimal mixture design (Mukherjee, Plakogiannis, 
2010) of CN-SNEFs. The mixture study included three 
components: the oil portion (represented by free fatty acid, 
A), the co-surfactant portion (represented by I308, B), and 
the surfactant portion (represented by Cr-El, C). 
COFA/I308/Cr-El system
This system was chosen as a model formulation 
to study the influence of time and drug loading on 
formulation turbidity upon aqueous dilution. Formulation 
turbidity was assessed by measuring the optical density 
at 600 nm (Date, Nagarsenker, 2007; Thakkar et al., 
2011). On the basis of preliminary self-emulsification 
and solubility data, the range for each component was 
selected as follows:
10 ≤ COFA ≤ 50
0 ≤ I308 ≤ 60
30 ≤ Cr-El ≤ 70
Total components = 100
The base design suggested 17 runs for the fitting of a 
special cubic model, a check for lack of fit, and an estimate 
of experimental error in formulation OD600 (Mukherjee, 
Plakogiannis, 2010).
The design included the assessment of five responses 
as follows: 
R1: OD600 after 5 min of aqueous dilution of CN-
free formulation; R2: OD600 after 1 h of aqueous dilution 
of CN-free formulation; R3: OD600 after 5 min of aqueous 
dilution of CN-equilibrated formulation; R4: OD600 after 
1 h of aqueous dilution of CN-equilibrated formulation; 
R5: OD600 after 2 h of aqueous dilution of CN-equilibrated 
formulation.
OL/I308/Cr-El system
On the basis of preliminary self-emulsification and 
solubility data, the range of each component was selected 
as follows: 
10 ≤ OL ≤ 30
10 ≤ I308 ≤ 40
30 ≤ Cr-El ≤ 70
Total components = 100
The base design suggested U_Pseudo coding with 16 
runs for the fitting of a quadratic model, a check for lack 
of fit, and an estimate of experimental error (Mukherjee, 
Plakogiannis, 2010).
The design included the assessment of three 
responses as follows: 
R1: droplet size after 1 h of aqueous dilution of 
drug-free formulation (nm); R2: droplet size after 1 h of 
aqueous dilution of drug-equilibrated formulation (nm); 
R3: equilibrium solubility (mg/g).
Cross polarizing light microscopy
Liquid SNEF samples were transferred onto 
microscope slides and coverslipped a few minutes prior 
to examination. Samples were then examined using 
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crossed polarized light microscopy (Carl Zeiss, Axio lab.
A1 (equipped with camera), Jena, Germany) (Mohsin, 
Long, Pouton, 2009; Mohsin, Pouton, 2012). Samples 
were examined for the existence of birefringence, a 
characteristic of liquid crystals, at a magnification of 40× 
(Kossena et al., 2004). Liquid crystalline (LC) phases 
were further identified as hexagonal or lamellar based on 
the observed birefringence patterns. Within the current 
study, liquid SNEF samples were examined to investigate 
the influence of CN loading on birefringence patterns in 
anhydrous samples, as well as 30% and 50% water dilution 
samples.
Determination of CN by using UPLC assay
CN was accurately quantified by using a recently 
reported UPLC reversed-phase method (Abdel-Hamid 
et al., 2012) with minor modifications. The mobile 
phase composition was altered to 0.5% trifluroacetic 
acid:acentonitrile (55:45) and the run time was increased 
to 1.5 min to allow for higher resolution between the 
intact drug and degradation product peaks. Separation was 
achieved using an Acquity® UPLC BEH C18 (2.1 × 50 
mm, 1.7 µm) column along with an Acquity guard filter, 
maintained at 50 ºC, and the flow rate was maintained at 
0.5 ml/min. The UV detector was set at 251 nm and the 
injection volume was 1.0 µl. 
Statistical analysis
The statistical significance of the results was 
analyzed using SPSS 22® software. One-way analysis of 
variance (ANOVA) followed by post hoc tests (LSD) were 
applied to compare solubility results (Atef, Belmonte, 
2008; Shahba, Mohsin, Alanazi, 2012a). A value of 
p < 0.05 was considered significant.
RESULTS AND DISCUSSION
Equilibrium solubility studies
CN solubility was previously screened in diverse 
formulation compositions (Shahba, Mohsin, Alanazi, 
2012a). In the current study, we aimed to maximize CN 
solubility and to develop a formulation design framework 
for weakly basic lipophilic drugs. Being a weak base, it 
was crucial to investigate the influence of formulation 
acidification on CN solubility. Formulation acidification 
was achieved using either an external acidifier (represented 
by HCl) or an internal acidifier (represented by free fatty 
acid present in the formulation).
Influence of external acidification on CN solubility
The influence of formulation acidification on CN 
solubility was investigated by acidifying SNEF by using 
37% HCl solution as the external acidifier. HCl solution 
was added to the formulation at 1%, 2%, and 5% w/w. 
Preliminary data revealed that 2% HCl acidification 
showed the highest CN solubilization. This finding 
might be explained by the high formulation water 
content that led to lower CN solubilization in case of 
5% acidification. 
The study involved investigating the acidification 
of two formulations: medium chain triglyceride (MCT) 
based-formulation and long chain fatty acid (LCFA) 
based-formulation. In case of MCT formulations, 2% 
acidification resulted in a 100% solubility increase 
relative to the non-acidified counterpart. However, the 
2% acidified LCFA formulation showed a 30% increase 
relative to the non-acidified counterpart (Figure 1). The 
solubility increase upon acidification complies with the 
fact that CN is a weak base and its solubility increases 
with decreasing pH (Gu et al., 2005). Similar results 
have been obtained with other weakly basic drugs, such 
as albendazole, which was shown to present increased 
solubility with increased concentrations of acidified 
PEG400 in the formulation (Mukherjee, Plakogiannis, 
2010). The solubility increase upon formulation 
FIGURE 1 - Influence of external formulation acidification 
on CN solubility. MCT: medium chain triglycerides, LCFA: 
long chain fatty acid. Non-acidified MCT formulation was 
represented by M812/I308/T85 (25/25/50); 2% acidified MCT 
formulation by M812/I308/T85/HCl (24/24/50/2); non-acidified 
LCFA formulation by OL/I308/Cr-El (25/25/50); 2% acidified 
LCFA formulation by OL/I308/Cr-El/HCl (24.5/24.5/49/2). a 
denotes significant difference (p < 0.05) from the corresponding 
non-acidified formulation. Data are expressed as mean ± S.D., 
n=3–6.
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acidification may be due to drug super-saturation or the 
transient formation of hydrochloride salts. 
Influence of internal acidification (free fatty acids 
versus ester form)
CN shows significant solubility increase upon 
increasing the acidity of aqueous systems (Gu et al., 2005). 
Interestingly, this phenomenon was also predominant in 
lipid-based systems (Figures 2 and 3).
Capric and caprylic acid (free fatty acids) 
formulations showed significantly (p<0.05) higher 
CN solubility relative to other capric/caprylic ester 
formulations (Figure 2). It seems that free fatty acids 
significantly increase CN solubility by acting as lipophilic 
solubilizers, as well as internal acidifiers.
Similarly, a COFA (high % of free lauric acid)-based 
formulation showed significantly (p<0.05) higher CN 
solubility relative to other lauric acid monoglycerides 
(esters) formulations (Figure 3).
Influence of fatty acid chain length
A more focused study was conducted to evaluate 
the influence of changing the fatty acid type within the 
formulation (Figure 4). CN solubility was significantly 
(p<0.05) increased upon decreasing fatty acid chain 
length. This finding may appear inconsistent with the 
finding of a previous study (Shahba, Mohsin, Alanazi, 
2012a) that showed higher CN solubility in long chain 
lipid formulations. However, thorough data review 
revealed that the previously compared formulations 
were uneven since the previous study (Shahba, Mohsin, 
Alanazi, 2012a) compared long chain free fatty acid with 
medium chain ester formulations. For a fair comparison, 
formulators should consider whether the evaluated fatty 
acid is in the free or ester form.
The phenomenon found in Figure 4 was correlated 
with the fact that the acid value of fatty acids increases 
as the fatty acid chain length decreases. Finally, a direct 
linear relationship was established between the reported 
acid value of the fatty acids in the formulation and CN 
solubility (Figure 5). CN solubility significantly (p<0.05) 
increased as the acid value increased. This point provides 
a suggested platform for the formulation design of weakly 
basic lipophilic drugs.
Self-emulsification assessment
Influence of external acidification
Medium chain glyceride formulations (acidified by 
HCl) showed satisfactory self-emulsification behavior 
upon water and acidic dilution at pH 1.2. However, all 
formulations (except for the 5% acidified formulation) 
presented indispersible flakes upon shifting from pH 1.2 
to pH 6.8 (Table I). This may be due to the interaction of 
the hydrochloride salt present in the formulation with the 
buffer salts of the alkaline media.
FIGURE 2 - Influence of internal formulation acidification on 
CN solubility in capric/caprylic acid-based formulations. MCT1 
denotes medium chain capric/caprylic triglycerides (M810), 
MCT2 denotes medium chain capric/caprylic triglycerides 
(M812), and MCM denotes medium chain capric/caprylic 
mono-glycerides (I308). *: Data adapted from Shahba, Mohsin, 
Alanazi, 2012a; a: significant difference (p < 0.05) from other 
formulations. Data are expressed as mean ± S.D., n = 3.
FIGURE 3 - Influence of internal formulation acidification 
on CN solubility in lauric acid-based formulations. PG-ML1 
denotes propylene glycol monolaurate (Lauroglycol 90), PG-
ML2 denotes propylene glycol monolaurate (Capmul PG-12). 
T20: Tween 20; Cr-RH40: Cremophor RH40; COFA: coconut 
oil free fatty acids (high % of lauric acid); MCM: medium chain 
capric/caprylic mono-glycerides (I308). a: significant difference 
(p < 0.05) from other formulations. Data are expressed as 
mean ± S.D., n = 3.
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Influence of internal acidification
Incorporation of free fatty acids in SNEFs offers 
dual advantages of serving as lipophilic portions as well 
as internal acidifiers within the formulation. Different fatty 
acids were assessed in order to explore their influence on 
formulation self-emulsifying efficiency. 
Although some formulations containing COFA 
showed efficient self-emulsification upon water and acidic 
dilution, they presented indispersible flakes upon shifting 
to pH 6.8 (Table II). A follow-up study was conducted 
to assess whether buffer salts interact with formulation 
components and produce these flakes. To distinguish the 
influence of the buffer salts, both formulation components 
and solution pH were maintained nearly equal while 
various buffer salts were investigated. COFA/I308/HCO-
60 (25/25/50) was selected as a control formulation and 
various buffer salts (with solution pH = 6.8 ± 1) were 
assessed (Table III). The model formulation presented 
poor homogeneity/dispersibility with all the investigated 
buffer salts. These results suggest that the poor self-
emulsification of the COFA formulation (at pH 6.8) might 
be related to the fatty acid itself rather than any interaction 
with the buffer salts.
Most capric acid (c10) and caprylic acid (c8) 
formulations showed excellent self-emulsification 
behavior upon acidic dilution (Table IV). However, they 
presented poor homogeneity/dispersibility upon shifting 
to pH 6.8. On the other hand, OL formulations exhibited 
superior performance compared with other fatty acids 
(Table V). Most of the tested formulations showed 
excellent self-emulsification in water, at pH 1.2, and even 
at pH 6.8. This observation is in agreement with recent 
studies (Larsen et al., 2012; Patel, Sarma, Vavia, 2013) 
where OL self-emulsifying formulations have exhibited 
excellent self-emulsification in all tested media. This 
promising OL characteristic might be explained by the 
low acid value of OL compared with other fatty acids 
(Figure 5) leading to a decreased precipitation tendency at 
pH 6.8. Another possible reason may be that OL is thought 
to behave as a co-surfactant at neutral pH (Larsen et al., 
2012).
The aforementioned discussion highlights the 
importance of conducting the self-emulsification 
assessment in three different media (distilled water, pH 
1.2, and pH 6.8), especially for weakly basic drugs. 
The usual practice of conducting the self-emulsification 
assessment in water only could lead to inaccurate excipient 
selection, resulting in wasted time and unsuccessful 
formulation optimization. 
Experimentally designed phase diagrams 
For each phase diagram, dots represented the 
investigated points in the design. Dots marked with a “2” 
or a “3” indicate points that were duplicated or triplicated, 
respectively. The analysis of response variables were 
carried out by using Design Expert® software. Data 
transformation was performed if necessary. Model fitting 
was carried out to select a model with insignificant lack-
of-fit, high adjusted and predicted R-squared values, small 
standard deviation, small predicted residual sum of squares 
(press), and no aliasing (Mukherjee, Plakogiannis, 2010). 
COFA/I308/Cr-El system
The D-optimal mixture design was applied to 
examine the influence of varying formulation components 
FIGURE 4 - Influence of fatty acid chain length on CN solubility. 
OL denotes oleic acid (c18) and COFA denotes coconut oil free 
fatty acids (high % of lauric acid, C12). Different letters above 
the bars indicate significant difference (p<0.05) between the 
solubility values. Data are expressed as mean ± S.D., n = 3–6.
FIGURE 5 - Influence of the acid value of the oil portion on CN 
solubility in the whole formulation. The oil portion represented 
25% of the formulation while the remaining excipients were 
kept constant as 25% I308 and 50% Cr-El. OL denotes oleic acid 
(c18) and COFA denotes coconut oil free fatty acids (high % of 
lauric acid, C12). Data are expressed as mean ± S.D., n = 3-6.
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TABLE I - Influence of HCl acidification on self-emulsification efficiency in medium chain glyceride formulations
Formulation 
(%W/W)
Excipient 
miscibility
Aqueous 
media
Homogeneity/ 
dispersibility Spontaneity
Overall 
performance
M812/I308/T85 
(25/25/50) miscible
D.W good < 1 min √
pH 1.2 good < 1 min √
shift to pH 6.8 poor - ×
M812/I308/T85/HCl 
(24.5/24.5/50/1) miscible
D.W good < 1 min √
pH 1.2 good < 1 min √
shift to pH 6.8 poor - ×
M812/I308/T85/HCl 
(24/24/50/2) miscible
D.W good < 1 min √
pH 1.2 good < 1 min √
shift to pH 6.8 poor - ×
M812/I308/T85/HCl 
(22.5/22.5/50/5) miscible
D.W moderate < 1 min √
pH 1.2 good < 1 min √
shift to pH 6.8 good - √
(√): good self-emulsifying efficiency; (×): poor self-emulsifying efficiency; M812: miglyol 812; I308: Imwitor 308; T85: tween 85. 
TABLE II - Influence of internal acidification by COFA on formulation self-emulsifying efficiency
Formulation (%W/W) Excipient miscibility
Aqueous 
media
Homogeneity/ 
dispersibility
Spontaneity 
(min)
Overall 
performance
COFA/I308/Cr-El 
(25/25/50) miscible
pH 1.2 poor < 1 ×
shift to pH 6.8 poor - ×
COFA/I308/Cr-El 
(10/20/70) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/S218/Cr-El 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/I308/T80 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/I308/T20 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/I308/PG/Cr-El 
(25/15/10/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/I308/M812/Cr-El 
(25/12.5/12.5/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/T85/Cr-El 
(33.3/33.3/33.3)
miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
COFA/I308/HCO-60 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
(√): good self-emulsifying efficiency; (×): poor self-emulsifying efficiency; COFA: coconut oil fatty acids; I308: Imwitor 308; 
S218: sefsol 218; Cr-El: cremophor El; M812: miglyol 812; T20: Tween 20; PG: propylene glycol; T80: Tween 80.
on formulation OD600 after aqueous dilution at five different 
stages (Figures 6 and 7). The first and second responses 
were conducted using CN-free formulation (Figure 6). 
There was no substantial difference between OD600 at 5 
min and 1 h after aqueous dilution of CN-free formulations 
(Figure 6 [A, B]). Both phase diagrams showed small 
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TABLE III - Influence of varying buffer solutions on formulation self-emulsifying efficiency
Formulation (%W/W) Buffer solution pH Homogeneity/ dispersibility
Spontaneity 
(min)
Overall 
performance
COFA/I308/HCO-60 
(25/25/50)
K2HPO4,KH2PO4,  
NaOH
7.5 poor < 1 ×
COFA/I308/HCO-60 
(25/25/50) Na2HPO4, KH2PO4 6.8 poor < 1 ×
COFA/I308/HCO-60 
(25/25/50)
 Na-acetate,  
0.1N HCl
5.9 poor < 1 ×
COFA/I308/HCO-60 
(25/25/50)
tri-Na citrate,  
0.1N HCl
6.65 poor < 1 ×
COFA/I308/HCO-60 
(25/25/50)
K2HPO4,  
0.1 N HCl
6.75 poor < 1 ×
COFA/I308/HCO-60 
(25/25/50)
Na-acetate,  
NaOH 
6.7 poor < 1 ×
(√): good self-emulsifying efficiency; (×): poor self-emulsifying efficiency; COFA: coconut oil fatty acids; I308: Imwitor 308.
TABLE IV - Influence of internal acidification by capric (c10) and caprylic (c8) acid on formulation self-emulsifying efficiency
Formulation (%W/W) Excipient miscibility
Aqueous 
media
Homogeneity/
dispersibility
Spontaneity 
(min)
Overall 
performance
Capric acid (c10)/I308/Cr-El 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
Capric acid (c10)/I308/T20 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
Capric acid (c10)/I308/Cr-RH40 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
Capric acid (c10)/I308/T85 
(25/25/50) miscible
pH 1.2 good 1–5 √
shift to pH 6.8 poor - ×
Capric acid (c10)/I308/HCO-30 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
Capric acid (c10)/I988/Cr-El 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
Caprylic acid (c8)/I308/Cr-El 
(25/25/50) miscible
pH 1.2 good < 1 √
shift to pH 6.8 poor - ×
(√): good self-emulsifying efficiency; (×): poor self-emulsifying efficiency; I308: Imwitor 308; I988: Imwitor 988; Cr-El: cremophor 
El; Cr-Rh40: cremophor RH40; T20: Tween 20; T85: Tween 85.
bluish and large turbid and milky areas. On the other 
hand, CN-equilibrated formulations showed significant 
decrease in OD600 compared to their CN-free counterparts 
(Figure 6 [A, B], Figure 7 [A, B]). At 5 min, the phase 
diagram showed large transparent and bluish areas 
with no existence of turbid or milky areas (Figure 7A). 
At subsequent (1 h and 2 h) samples, OD600 showed a 
gradual shift upwards and a turbid area started to appear 
at the expense of the transparent area (Figure 7 [B,C]). 
It is worth noticing that all formulations showed sharply 
lower OD600 values after equilibration with CN. This is 
an unusual phenomenon because CN is a PWSD and 
its incorporation was expected to increase formulation 
turbidity upon aqueous dilution. For further investigation 
Optimization of self-nanoemulsifying formulations for weakly basic lipophilic drugs: role of acidification and experimental design 661
TABLE V - Influence of internal acidification by OL on formulation self-emulsifying efficiency
Formulation 
(%W/W) Aqueous media
 Excipient 
miscibility
Homogeneity/
dispersibility
Spontaneity 
(min)
Overall 
performance
OL/I308/Cr-El 
(25/25/50)
pH 1.2
miscible
good < 1 √
shift to pH 6.8 good - √
OL/I308/Cr-El 
(30/30/40)
pH 1.2
miscible
good < 1 √
shift to pH 6.8 good - √
OL/I308/Cr-El 
(30/40/30)
pH 1.2
miscible
poor < 1 ×
shift to pH 6.8 poor - ×
OL/I308/HCO-60 
(30/40/30)
pH 1.2
miscible
good < 1 √
shift to pH 6.8 good - √
OL/I308/HCO-60 
(25/25/50)
pH 1.2
immiscible
good < 1 ×
shift to pH 6.8 good - ×
(√): good self-emulsifying efficiency; (×): poor self-emulsifying efficiency; OL: oleic acid, I308; Imwitor 308, Cr-El; cremophor El
FIGURE 6 - Mixture design for the COFA/I308/Cr-El system showing: (A1) phase diagram; (A2): 3D plot of OD600 after 5 min 
of aqueous dilution of CN-free formulation; (B1) phase diagram; (B2): 3D plot of OD600 after 1 h of aqueous dilution of CN-free 
formulation. COFA denotes coconut oil fatty acids, I308: Imwitor 308, and Cr-El: cremophor El.
A. Abdul-Wahhab Shahba, K. Mohsin, F. K. Alanazi, S. I. Abdel-Rahman662
of this phenomenon, another system was investigated 
using OL, rather than COFA, as the oil component.
OL/I308/Cr-El system
D-optimal mixture design was applied to examine the 
influence of varying formulation components on droplet size 
and equilibrium solubility. The droplet size of the diluted 
CN-free formulations showed high variability, ranging from 
less than 100 nm up to ≈ 1250 nm (Figure 8A). Formulations 
with droplet size above 100 nm are expected to show a 
turbid or milky appearance (Shahba, Mohsin, Alanazi, 
FIGURE 7 - Mixture design for COFA/I308/Cr-El system showing: (A1) phase diagram; (A2) 3D plot of OD600 after 5 min of 
aqueous dilution of CN-equilibrated formulation; (B1) phase diagram; (B2) 3D plot of OD600 after 1 h of aqueous dilution of CN-
equilibrated formulation; (C1) phase diagram; (C2) 3D plot of OD600 after 2 h of aqueous dilution of CN-equilibrated formulation. 
COFA denotes coconut oil fatty acids, I308: Imwitor 308, and Cr-El: cremophor El.
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2012b). However, formulation phase behavior completely 
changed upon CN incorporation (Figure 8B). Diluted 
CN-equilibrated formulations showed less variability and 
significantly smaller droplet sizes, with a maximum of 87 
nm. This observation closely matches the results obtained 
in the previous COFA/I308/Cr-El phase diagram, where the 
incorporation of CN led to smaller droplet sizes, decreased 
turbidity, and increased SNEF efficiency. Many researchers 
have examined the influence of PWSD incorporation into 
SNEFs on droplet size. Some articles showed droplet 
size increases upon drug incorporation (Kommuru et al., 
2001; Kang et al., 2004), while a few articles showed no 
droplet size difference upon drug incorporation (Nielsen 
et al., 2007). However, one recent publication showed 
significant droplet size decrease upon drug incorporation 
(Patel, Sarma, Vavia, 2013). This last publication may be 
in agreement with the current work because it has also 
investigated a very similar formulation composition (OL/
medium chain monoglycerides/Cr-El) with a weakly basic 
drug (lumefantrine). According to that recent publication 
(Patel, Sarma, Vavia, 2013), this phenomenon might be due 
to the interaction between the drug amine group and the 
OL carboxylic group, which leads to the formation of an 
ion-pairing complex. The formed complex presented more 
efficient self-emulsification and lower droplet sizes than the 
drug-free formulation. The observed phenomenon could be 
extrapolated for other weakly basic lipophilic drugs. 
The third response involved the equilibrium CN 
solubility in anhydrous SNEFs (Figure 8C). Maximum CN 
solubility was achieved using higher OL and lower Cr-El 
proportions. This result matches the solubility data, which 
showed a significant (p < 0.05) rise in CN solubility upon 
increasing the free fatty acid proportion in the formulation 
(Figure 3).
Experimental model validation
To achieve the optimum CN-SNEF, it was desirable 
to select the formulation presenting lower droplet size and 
higher CN solubility. The formulation [OL/I308/Cr-El 
(25/25/50)] was selected as a confirmation point to validate 
the predictions of the experimental model. The design 
was utilized to predict the three design responses for this 
formulation. Experiments were then conducted to obtain 
the actual response values. All the actual mean values were 
close to the predicted mean, and fall between the 95% 
lower and higher prediction intervals (Table VI). These 
results confirm the model accuracy in predicting different 
design responses. The selected formulation showed ultra-
fine (43 nm) droplet size (in case of CN loading), high (88 
mg/g) CN solubility, and therefore has great potential to 
present an efficient CN-SNEF. These results match the 
recently reported data regarding CN-SNEFs (Shahba, 
Mohsin, Alanazi, 2012a).
Cross polarizing light microscopy
The optimal liquid SNEF (OL/I308/Cr-El [25/25/50)] 
was examined to investigate the influence of CN loading 
on the birefringence pattern in anhydrous samples, as well 
as 30% and 50% water dilutions. Anhydrous liquid SNEF 
showed a transparent isotropic oily phase in both CN-free 
and CN-equilibrated samples. After hydration, CN-free 
liquid SNEF showed a two-phase emulsion mixture 
(without LC) at both 30% and 50% water ratios (Figure 
9A, B). However, hydrated samples of CN-loaded SNEF 
became more transparent and presented a birefringent LC 
phase at 50% water ratio (Figure 9C, D). On the basis of 
the observed pattern, this sample was identified as lamellar 
LC phase (Mohsin, Long, Pouton, 2009; Mohsin, Pouton, 
2012). The presence of a lamellar LC phase could lead to 
the enhancement of the formulation self-emulsification 
efficiency. A very recent article (Lee et al., 2016) showed 
pronounced enhancement of bioavailability upon using 
lamellar LC nanoparticles. It is worth noticing that the LC 
phase was only observed in the CN-loaded formulation. 
This is in close correlation with the phenomenon observed 
in experimentally designed phase diagrams, which showed 
enhanced SNEF efficiency upon CN incorporation into 
the formulation. 
CONCLUSION
Pre-competitive research should be promoted to 
build-up advanced formulation design frameworks for 
different PSWD categories. In the current study, we 
investigated the weakly basic lipophilic drug category 
by using CN as a model. The formulation acidity and the 
pH of the dispersion media were found to exert strong 
influences on drug solubility and formulation efficiency, 
respectively. Formulation acidification produced 
significant drug solubility increase. It was critical to 
conduct the self-emulsification assessment in media 
with different pH rather than water alone. This step is 
of particular importance for weakly basic drugs. OL 
was found to be a vital component in the development 
of SNEFs for weakly basic lipophilic drugs. It offers 
several advantages, serving as a lipophilic solubilizer, an 
internal acidifier, along with maintaining excellent self-
nanoemulsification efficiency. As shown in the current 
study, experimentally designed phase diagrams could be 
easily utilized for fast, accurate, and reliable optimization 
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of SNEFs. Future work may involve in vitro dissolution 
and lipolysis studies in formulation optimization 
by experimental design. The adopted optimization 
approach explored critical characterization issues, the 
role of formulation acidification, SNEF optimization by 
experimental design, and can be generalized for the whole 
category of weakly basic lipophilic drugs.
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